MerTK kinase domain with type 3 inhibitor from a DNA-encoded library

Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.

Proto-oncogene c-Mer,Receptor tyrosine kinase MerTK

0.3 mM protein co-crystallised with 0.5 mM compound (1 % DMSO) in 25 % PEG3350, 0.2 M MgCl2, 0.1 M PCTP pH 7.5

Tyrosine-protein kinase Mer (E.C.2.7.10.1)

tyrosine kinase, inhibitor, type3 kinase inhibitor, structure-based drug design, oncology, SIGNALING PROTEIN